Drug Delivery Systems Based on Hydroxyethyl Starch.

The advantageous biological properties of hydroxyethyl starch (HES) triggered research interest toward the design and synthesis of drug delivery systems (DDSs) based on this polysaccharide. Convenient reaction schemes, including one-step reactions, led to the synthesis of HES conjugates with selected anticancer molecules or therapeutic proteins. Nanocapsules and hydrogels based on HES were also prepared and studied as prospective drug delivery systems. Formulations originating from these drug conjugates and also from nanocapsules and hydrogels loaded with drugs were characterized, highlighting the extension of their half-life in plasma, which is a critical property as far as their efficacy is concerned. Results obtained in vitro and in vivo proved promising, justifying the undertaking of additional experiments with such systems, including their multifunctionalization. The promising formulations that are discussed in this Topical Review is expected to further increase interest in applying HES for molecular constructing novel DDSs with enhanced efficacy, which may, in the future, find clinical applications.

[1]  Ashish Ranjan Sharma,et al.  Next Generation Delivery System for Proteins and Genes of Therapeutic Purpose: Why and How? , 2014, BioMed research international.

[2]  Shewaye Lakew Mekuria,et al.  Polysaccharide based nanogels in the drug delivery system: Application as the carrier of pharmaceutical agents. , 2016, Materials science & engineering. C, Materials for biological applications.

[3]  J. Boldt.  Modern Rapidly Degradable Hydroxyethyl Starches: Current Concepts , 2009, Anesthesia and analgesia.

[4]  Changren Zhou,et al.  Polysaccharides-based nanoparticles as drug delivery systems. , 2008, Advanced drug delivery reviews.

[5]  P. Caliceti,et al.  Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers , 2013, Journal of drug delivery.

[6]  G. Hause,et al.  Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. , 2007, Biomacromolecules.

[7]  Dmitry Nevozhay,et al.  Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier. , 2006, Anticancer research.

[8]  R. Daniels,et al.  A new hydrogel drug delivery system based on Hydroxyethylstarch derivatives , 2010, Journal of microencapsulation.

[9]  N. Zhang,et al.  Polysaccharide-Based Micelles for Drug Delivery , 2013, Pharmaceutics.

[10]  Xiaofei Chen,et al.  pH‐sensitive hydroxyethyl starch–doxorubicin conjugates as antitumor prodrugs with enhanced anticancer efficacy , 2015 .

[11]  R. Daniels,et al.  Influence of degree of substitution of HES-HEMA on the release of incorporated drug models from corresponding hydrogels. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  Gerhard Winter,et al.  Head to head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra. , 2015, Journal of pharmaceutical sciences.

[13]  Anderson Ep,et al.  BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS). , 1963 .

[14]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[15]  Baorui Liu,et al.  10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[16]  N. Rapoport,et al.  Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. , 2010, Molecular pharmaceutics.

[17]  J. R. Vargas,et al.  Fifteen years of cell-penetrating, guanidinium-rich molecular transporters: basic science, research tools, and clinical applications. , 2013, Accounts of chemical research.

[18]  A. Palmer,et al.  Site-selective glycosylation of hemoglobin with variable molecular weight oligosaccharides: potential alternative to PEGylation. , 2012, Journal of the American Chemical Society.

[19]  K. Landfester,et al.  (Oligo)mannose functionalized hydroxyethyl starch nanocapsules: en route to drug delivery systems with targeting properties. , 2013, Journal of materials chemistry. B.

[20]  Z. Sideratou,et al.  Triphenylphosphonium Decorated Liposomes and Dendritic Polymers: Prospective Second Generation Drug Delivery Systems for Targeting Mitochondria. , 2016, Molecular pharmaceutics.

[21]  E. P. Anderson,et al.  BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS). , 1963, Annual review of biochemistry.

[22]  S. Kozek-Langenecker,et al.  Effects of Hydroxyethyl Starch Solutions on Hemostasis , 2005, Anesthesiology.

[23]  G. Gregoriadis,et al.  Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.

[24]  R. Kontermann,et al.  Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives , 2012 .

[25]  Yoon Yeo,et al.  Recent advances in stealth coating of nanoparticle drug delivery systems. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[26]  Z. Sideratou,et al.  Carboxylated Hydroxyethyl Starch: A novel Polysaccharide for the Delivery of Doxorubicin , 2015, Chemical biology & drug design.

[27]  H. Ringsdorf.  Structure and properties of pharmacologically active polymers , 1975 .

[28]  Wim E Hennink,et al.  Hydrogels for Therapeutic Delivery: Current Developments and Future Directions. , 2017, Biomacromolecules.

[29]  Matej Bračič,et al.  Polysaccharides in Medical Applications , 2018 .

[30]  En-Wei Lin,et al.  Therapeutic protein-polymer conjugates: advancing beyond PEGylation. , 2014, Journal of the American Chemical Society.

[31]  J. Boratýnski,et al.  Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy , 2014, Pharmacology research & perspectives.

[32]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[33]  A. Mahmood,et al.  Delivery of Therapeutic Proteins: Challenges and Strategies. , 2016, Current drug targets.

[34]  R. Kontermann,et al.  Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.

[35]  S. Nair,et al.  A systematic evaluation of hydroxyethyl starch as a potential nanocarrier for parenteral drug delivery. , 2015, International journal of biological macromolecules.

[36]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[37]  G. Winter,et al.  The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes. , 2013, Biomaterials.

[38]  Huibi Xu,et al.  Redox-Sensitive Hydroxyethyl Starch-Doxorubicin Conjugate for Tumor Targeted Drug Delivery. , 2016, ACS applied materials & interfaces.

[39]  Cuifang Cai,et al.  Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin. , 2014, International journal of pharmaceutics.

[40]  K. Landfester,et al.  Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch nanocapsules. , 2012, Biomacromolecules.

[41]  Z. Sideratou,et al.  Drug delivery using multifunctional dendrimers and hyperbranched polymers , 2010, Expert opinion on drug delivery.

[42]  L. Brochard,et al.  Preferred plasma volume expanders for critically ill patients: results of an international survey , 2004, Intensive Care Medicine.

[43]  D. Kaplan,et al.  Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery. , 2015, Bioconjugate chemistry.

[44]  Dean A Fergusson,et al.  Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. , 2013, JAMA.

[45]  G. Pasut.  Polymers for Protein Conjugation , 2014 .

[46]  Theresa M. Allen,et al.  Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[47]  A. Maity,et al.  Limited Efficiency of Drug Delivery to Specific Intracellular Organelles Using Subcellularly "Targeted" Drug Delivery Systems. , 2016, Molecular pharmaceutics.

[48]  G. Winter,et al.  Challenges for PEGylated Proteins and Alternative Half-Life Extension Technologies Based on Biodegradable Polymers , 2013 .

[49]  X. Zhu,et al.  Polysaccharides for drug delivery and pharmaceutical applications , 2006 .

[50]  S. Balu-Iyer,et al.  Delivery of therapeutic proteins. , 2010, Journal of pharmaceutical sciences.

[51]  Xing Tang,et al.  A novel 5-fluorouracil prodrug using hydroxyethyl starch as a macromolecular carrier for sustained release , 2012 .

[52]  Roman Mathaes,et al.  Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.